|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.5000 - 4.5000|
|52 Week Range||2.0000 - 7.0000|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sun BioPharma, Inc. (SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today summarized initial Phase 1 clinical data for SBP-101, which was presented in a poster session at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in cell function in multiple tumor types. Based upon the study data presented today, the adverse event profile of SBP-101 at the optimal dose level was manageable and an expansion study in patients with pancreatic ductal adenocarcinoma (PDA) is planned to begin during the second quarter of 2020.
Sun BioPharma, Inc. (SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today announced that an abstract describing Phase 1 clinical data for SBP-101 has been accepted for poster presentation January 24, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium, being held January 23-25 in San Francisco. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) a metabolic pathway of critical importance in multiple tumor types. Sun BioPharma also announced that Arthur J. Fratamico, RPh, MBA recently joined its Board of Directors.
Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort plannedNew U.S. sites added in anticipation of further clinical developmentCompany raised $3.1.
Enrollment in Third Cohort of PDA Combination Study is Encouraging Preliminary Efficacy Signals Improve with New Data Regarding Second CohortEntire.
Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides an update on the Company’s current clinical trial. Following successful conclusion of the first SBP-101 dose escalation study in heavily pretreated pancreatic cancer patients that showed SBP-101 could be administered safely as monotherapy, a second Phase 1 safety study entitled, “SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel in Newly Diagnosed Patients with Metastatic Pancreatic Ductal Adenocarcinoma” was undertaken to evaluate the addition of SBP-101 to front line gemcitabine and nab-paclitaxel treatment.
Enrollment in Second Cohort of PDA Combination Study CompletedNew Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 -- Sun BioPharma, Inc. (OTCQB:SNBP), a.
Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as.